Key Highlights

● Moderna soared $28.00 to $225.00 on volume of 28.9 million shares.

● The initiative would start in December with a focus on three cancers.

● Novavax, BioNTech, Arcturus and Vaxcyte also rallied.

● No funding amounts or corporate partners were confirmed.

A report said that the National Institutes of Health plans a public-private campaign, involving the NIH's foundation, to fast-track cancer treatment research starting in December. According to the report, the initial focus will be pancreatic, liver and colorectal cancers, along with some childhood tumours, and the aim is to replicate the success of the effort that produced Covid-19 vaccines in record time.

No dollar figure or list of corporate partners was confirmed on Friday. Even so, the idea of a federal push modelled on the pandemic response was enough to send investors searching for any company with a credible cancer-vaccine or rapid-development story.

Moderna leads the charge

Moderna (NASDAQ:MRNA), whose messenger RNA technology was central to the Covid vaccine programme, rocketed $28.00 to $225.00, its highest level since 2021. It traded between $197.17 and $225.00 on volume of about 28.9 million shares, well above its 17.7 million average. The day also marked Moderna's official entry into the Nasdaq-100, where it replaced Warner Bros. Discovery (NASDAQ:WBD). Some coverage attributed part of the move to that index entry, while others pointed to the report as the main driver.

The wider vaccine group

The rally spread quickly. Novavax (NASDAQ:NVAX) soared, though it was noted that no company announcement or filing explained its move specifically. BioNTech (NASDAQ:BNTX) rose to about $92.44. Arcturus Therapeutics (NASDAQ:ARCT) jumped to about $14.10 after Leerink Partners analyst Lili Nsongo kept an Outperform rating and raised the price target to $19 from $13. Vaxcyte (NASDAQ:PCVX) climbed to about $65.05.

Bigger names joined in. Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Gilead all rose, helping health care finish as one of the strongest S&P 500 sectors.

Beyond vaccines: tools and platforms

The report also lifted companies that supply the technology behind fast drug development. Ginkgo Bioworks (NYSE:DNA) rallied to about $12.74; it separately said it will provide in-kind access to its autonomous Boston lab for the National Science Foundation's X-Labs programme, and its gain was also linked to the report. Twist Bioscience (NASDAQ:TWST), which makes synthetic DNA, climbed to about $165.19 without a same-day catalyst.

AI-driven drug discovery names Recursion Pharmaceuticals and Tempus AI also rose, according to market data.

Among micro-caps, cancer-immunotherapy developer PDS Biotechnology (NASDAQ:PDSB) and Cue Biopharma (NASDAQ:CUE) posted large gains without company-specific news. No company announcement explained those moves, and low-priced, thinly traded shares can swing sharply in both directions.

Why the reaction was so strong

Biotech is a sector where government policy can change the economics of research overnight. A coordinated federal programme can mean faster regulatory pathways, shared funding and quicker patient enrolment. Investors had little detail on Friday, so the moves reflect hopes about what the initiative could become rather than signed contracts.

The rally also came against a supportive tape, with health care finishing as the second-best S&P 500 sector behind real estate. The S&P 500 rose 46.18 points to 7,811.54, and the Nasdaq Composite added 172.83 points to 27,366.17.

Official NIH Details Will Decide Whether the Rally Holds

Investors will look for official confirmation and details from the NIH, including any partners and funding, ahead of the December start. Johnson & Johnson (NYSE:JNJ) reports on Tuesday, October 13, and September consumer prices arrive Wednesday, October 14. Monday, October 12 brings a stock session but no bond trading, because of Columbus Day. The Fed meets October 27–28.